Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture. Tilde Bio, Inc. (FL110) is building a next-generation biological sensing platform at the intersection of synthetic biology, protein engineering, nanopore biophysics, electrophysiology, signal processing, and machine learning.